← Back to Screener
Kiora Pharmaceuticals, Inc. Common Stock (KPRX)
Price$2.52
Favorite Metrics
Price vs S&P 500 (26W)-15.41%
Price vs S&P 500 (4W)11.08%
Market Capitalization$9.96M
P/E Ratio (Annual)2.77x
All Metrics
P/CF (Annual)1.16x
Book Value / Share (Quarterly)$6.53
P/TBV (Annual)0.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)81.26%
Cash Flow / Share (Quarterly)$-2.92
Price vs S&P 500 (YTD)23.78%
Net Profit Margin (TTM)70.11%
EPS (TTM)$-2.05
10-Day Avg Trading Volume2.86M
EPS Excl Extra (TTM)$-2.05
Revenue Growth (5Y)108.15%
EPS (Annual)$0.87
ROI (Annual)13.95%
Net Profit Margin (5Y Avg)-17004.21%
Cash / Share (Quarterly)$5.64
P/E Normalized (Annual)2.77x
ROA (Last FY)9.85%
EBITD / Share (TTM)$-1.96
ROE (5Y Avg)-103.98%
Operating Margin (TTM)66.65%
Cash Flow / Share (Annual)$2.85
P/B Ratio0.44x
P/B Ratio (Quarterly)0.43x
Net Income / Employee (Annual)$0
Net Interest Coverage (TTM)-8.86x
ROA (TTM)-25.82%
EV / EBITDA (TTM)1.00x
EPS Incl Extra (Annual)$0.87
Current Ratio (Annual)4.94x
Quick Ratio (Quarterly)8.29x
3-Month Avg Trading Volume0.36M
52-Week Price Return-8.36%
EV / Free Cash Flow (Annual)0.52x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.58
P/S Ratio (Annual)0.62x
Asset Turnover (Annual)0.44x
52-Week High$4.18
Operating Margin (5Y Avg)-17089.00%
EPS Excl Extra (Annual)$0.87
26-Week Price Return-6.67%
Quick Ratio (Annual)4.71x
13-Week Price Return13.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.79x
Enterprise Value$4.447
Revenue / Share Growth (5Y)-28.30%
Asset Turnover (TTM)0.38x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)35.33%
Cash / Share (Annual)$8.93
3-Month Return Std Dev82.13%
Net Income / Employee (TTM)$-1
ROE (Last FY)13.95%
Net Interest Coverage (Annual)-2.61x
EPS Basic Excl Extra (Annual)$0.87
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.05
ROI (TTM)-36.35%
P/S Ratio (TTM)0.62x
Pretax Margin (5Y Avg)-17045.28%
Revenue / Share (Annual)$3.88
Tangible BV / Share (Annual)$6.36
Price vs S&P 500 (52W)-43.46%
Year-to-Date Return27.92%
5-Day Price Return3.28%
EPS Normalized (Annual)$0.87
ROA (5Y Avg)-55.18%
Net Profit Margin (Annual)22.44%
Month-to-Date Return30.57%
Cash Flow / Share (TTM)$-6.49
EBITD / Share (Annual)$1.08
Operating Margin (Annual)27.50%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-103.09%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.05
P/TBV (Quarterly)0.61x
P/B Ratio (Annual)0.38x
Pretax Margin (TTM)70.11%
Book Value / Share (Annual)$8.58
Price vs S&P 500 (13W)10.65%
Beta-0.46x
P/FCF (Annual)1.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-36.35%
52-Week Low$1.76
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KPRXKiora Pharmaceuticals, Inc. Common Stock | 0.62x | — | — | — | $2.52 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for rare retinal diseases. Its lead program, KIO-301, is a molecular photoswitch designed to restore vision in inherited retinal degenerative diseases including retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also advancing KIO-104, a non-steroidal immunomodulator for posterior non-infectious uveitis.